A Form 4 filed on September 3, 2026 reports that David Hollander, Chief R&D Officer of Veradermics, Inc. (NYSE:MANE), acquired 9,650 restricted stock units and a stock option covering 19,300 shares of common stock, both granted on September 1, 2026 at no cost to the reporting person.

Key Highlights

  • RSU Grant: David Hollander received 9,650 restricted stock units on September 1, 2026 at a price of $0, resulting in direct beneficial ownership of 9,650 shares following the transaction.
  • Stock Option Grant: Hollander also received a stock option to purchase 19,300 shares of common stock at an exercise price of $97.51, expiring September 1, 2036.
  • RSU Vesting Schedule: The RSUs vest 25% on each anniversary of the September 1, 2026 grant date, with full vesting completed by September 1, 2030, subject to continued service.
  • Option Vesting Schedule: The option vests 25% on September 1, 2027, with the remaining shares vesting in equal monthly installments over 36 months thereafter, subject to continued service.
  • Plan: The RSUs were granted under the Veradermics, Incorporated 2026 Incentive Plan, according to the filing.
  • Reporting Person Role: Hollander is identified in the filing as Chief R&D Officer of Veradermics, Inc.

Veradermics Grants Equity Awards to Chief R&D Officer Under 2026 Incentive Plan

According to the Form 4 filed with the U.S. Securities and Exchange Commission, David Hollander, Chief R&D Officer of Veradermics, Inc., acquired two equity awards on September 1, 2026. The first is a grant of 9,650 restricted stock units under the Veradermics, Incorporated 2026 Incentive Plan. The filing states that "each RSU represents a contingent right to receive one share of Common Stock." Both awards were acquired at a reported price of $0 to the reporting person.

The RSUs are subject to a four-year vesting schedule, vesting 25% on each of September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030, contingent on continued service. Following the transaction, the filing reports Hollander holds 9,650 shares of common stock directly as a result of the RSU grant.

The second award is a stock option granting the right to purchase 19,300 shares of common stock at an exercise price of $97.51 per share, with an expiration date of September 1, 2036. The filing indicates the option vests as to 25% of the underlying shares on September 1, 2027, with the remaining shares vesting in equal monthly installments over 36 months after that date, subject to continued service. Following this transaction, the filing reports Hollander beneficially owns 19,300 derivative securities directly. The Form 4 was signed by Michael Greco as Attorney-in-Fact on September 3, 2026.

What Was Disclosed

Veradermics, Inc. Chief R&D Officer David Hollander reported receiving 9,650 RSUs and a stock option to purchase 19,300 shares at $97.51, both granted September 1, 2026 under the company's 2026 Incentive Plan, with four-year vesting schedules tied to continued service.